-
and prospects for immunotherapy against relapsed or refractory haematological cancers. Phase I clinical trial to assess the feasibility and safety of allogeneic CD19-CAR-NK therapy for patients with
-
Higher Engineering). Master's degree or accredited postgraduate training in bioengineering or studies related to the biomedical field (Biomedical Engineering, Biotechnology, Materials, etc.). 1 year of
-
degree level 3. Master's degree in Clinical Trial Monitoring completed at the time of recruitment. 1 year of experience in similar positions. English qualification (minimum B1). LanguagesENGLISHLevelBasic
Enter an email to receive alerts for 1' positions